ACDM News Item

Regulatory Considerations DMEG to Review Health Canada’s Draft Guidance

Date: August 4, 2026

Thank you to the Regulatory Considerations DMEG for sharing this update.

Health Canada published a Draft guidance on decentralized clinical trials. This is part of Health Canada’s effort to modernize clinical trial regulation to allow for new trial types and designs. The guidance applies to phase I-IV trials involving pharmaceuticals, biologics and radiopharmaceuticals intended for human use. It does not apply to medical devices, natural health projects or foods for special dietary purposes.

The ACDM Regulatory Considerations DMEG will be reviewing the draft guidance and publishing a summary of the points that impact data managers. In the interim you can read the draft guidance here: Health Canada Draft guidance on decentralized clinical trials or download here.

Meet the DMEG here

Explore More News

Regulatory Considerations DMEG Shares Update on ICH E6(R3) Training Modules Available

The ICH Working Groups and The ICH Training Associates have released two new training . . .

Recent update from the regulatory landscape in clinical data management

On 22 September, MHRA published a new set of inspection dossier documents specifically for . . .

Regulatory Considerations DMEG Update – August 2026

Please read the following update from the Regulatory Considerations DMEG: July and . . .

Get to know ACDM Board Member: Santosh Karthikeyan Viswanathan

We caught up with one of ACDM’s new Board Members, Santosh Karthikeyan Viswanathan, to . . .

Guidance on Decentralized Clinical Trials to be Reviewed by the ACDM RC DMEG

Health Canada (HC) continues to publish new guidelines to support their modernization of . . .

Regulatory Considerations DMEG to Review Health Canada’s Draft Guidance

Thank you to the Regulatory Considerations DMEG for sharing this update. Health Canada . . .

Recent update from the regulatory landscape in clinical data management

Thank you to the Regulatory Considerations DMEG for sharing this update. On July 15 the . . .

Regulatory Considerations DMEG Update – June 2026

Please read the following update from the Regulatory Considerations DMEG: Regulators have . . .

FDA Announces New Initiative for Real-Time Clinical Trials

The U.S. Food and Drug Administration (FDA) has announced a new initiative to support the . . .

Get to know ACDM Board Member Jennifer Duff

We caught up with one of ACDM’s new Board Members, Jennifer Duff, to learn more about her. . . .

Recent News in Regulatory Landscape

The ACDM Regulatory Considerations DMEG have kindly put together a short news piece . . .

Real-Time Clinical Data Flow: Why the FDA’s New Pilot Validates the Data Flow Modernization Agenda

Tamer Chowdhury, on behalf of ACDM Technology DMEG. On April 28, FDA Commissioner Dr. . . .